| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Immunohematology and Blood Transfusion and
Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; and
Divisions of Immunology, Cellular Biochemistry, and Molecular Genetics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Encounter of Ag by naive T cells can lead to T cell priming as well as tolerance. The balance between immunity and tolerance is controlled by the conditions of Ag encounter and the activation status of the APC. We have investigated the rules that govern this balance in case an environment that normally induces tolerance is reverted into a milieu that promotes T cell priming, using a minimal CTL epitope derived from human adenovirus type 5 E1A. Vaccination of mice s.c. with E1A peptide in IFA readily induces CTL tolerance, resulting in the inability to control E1A-expressing tumors. The present study shows that efficient CTL priming is achieved when this peptide vaccine is combined with systemic administration of APC-activating compounds like agonistic anti-CD40 mAb or polyriboinosinate-polyribocytidylate. Surprisingly, this CTL response is not long-lasting and therefore fails to protect against tumor outgrowth. Disappearance of CTL reactivity was strongly associated with systemic persistence of the peptide for >200 days. In contrast, peptide administered in PBS does not persist and generates long term CTL immunity capable of rejecting Ad5E1A-positive tumors, when combined with CD40 triggering. Thus, presentation of CTL epitopes in an appropriate costimulatory setting by activated APC, although being essential and sufficient for CTL priming, eventually results in tolerance when the Ag persists systemically for prolonged times. These observations are important for the development of immune intervention schemes in autoimmunity and cancer.
This article has been cited by other articles:
|
|
 |
|
  V. Pulko, X. Liu, C. J. Krco, K. J. Harris, X. Frigola, E. D. Kwon, and H. Dong TLR3-Stimulated Dendritic Cells Up-regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor Vaccination J. Immunol., September 15, 2009; 183(6): 3634 - 3641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Bijker, S. J. F. van den Eeden, K. L. Franken, C. J. M. Melief, R. Offringa, and S. H. van der Burg CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund's Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity J. Immunol., October 15, 2007; 179(8): 5033 - 5040. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. de Witte, M. Toebes, J.-Y. Song, M. C. Wolkers, and T. N. M. Schumacher Effective graft depletion of MiHAg T-cell specificities and consequences for graft-versus-host disease Blood, May 1, 2007; 109(9): 3830 - 3838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bartholdy, S. O. Kauffmann, J. P. Christensen, and A. R. Thomsen Agonistic Anti-CD40 Antibody Profoundly Suppresses the Immune Response to Infection with Lymphocytic Choriomeningitis Virus J. Immunol., February 1, 2007; 178(3): 1662 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Hamilton-Williams, A. Lang, D. Benke, G. M. Davey, K.-H. Wiesmuller, and C. Kurts Cutting Edge: TLR Ligands Are Not Sufficient to Break Cross-Tolerance to Self-Antigens J. Immunol., February 1, 2005; 174(3): 1159 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Th. den Boer, G. J. D. van Mierlo, M. F. Fransen, C. J. M. Melief, R. Offringa, and R. E. M. Toes The Tumoricidal Activity of Memory CD8+ T Cells Is Hampered by Persistent Systemic Antigen, but Full Functional Capacity Is Regained in an Antigen-Free Environment J. Immunol., May 15, 2004; 172(10): 6074 - 6079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Bronte, S. Cingarlini, E. Apolloni, P. Serafini, I. Marigo, C. De Santo, B. Macino, O. Marin, and P. Zanovello Effective Genetic Vaccination with a Widely Shared Endogenous Retroviral Tumor Antigen Requires CD40 Stimulation during Tumor Rejection Phase J. Immunol., December 15, 2003; 171(12): 6396 - 6405. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Haicheur, F. Benchetrit, M. Amessou, C. Leclerc, T. Falguieres, C. Fayolle, E. Bismuth, W. H. Fridman, L. Johannes, and E. Tartour The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization Int. Immunol., October 1, 2003; 15(10): 1161 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mehrotra, R. Stevens, R. Zengou, N. G. Chakraborty, L. H. Butterfield, J. S. Economou, D. I. Dorsky, and B. Mukherji Regulation of Melanoma Epitope-specific Cytolytic T Lymphocyte Response by Immature and Activated Dendritic Cells, in Vitro Cancer Res., September 1, 2003; 63(17): 5607 - 5614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Stober, I. Jomantaite, R. Schirmbeck, and J. Reimann NKT Cells Provide Help for Dendritic Cell-Dependent Priming of MHC Class I-Restricted CD8+ T Cells In Vivo J. Immunol., March 1, 2003; 170(5): 2540 - 2548. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cremer, M.-C. Dieu-Nosjean, S. Marechal, C. Dezutter-Dambuyant, S. Goddard, D. Adams, N. Winter, C. Menetrier-Caux, C. Sautes-Fridman, W. H. Fridman, et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction Blood, November 15, 2002; 100(10): 3646 - 3655. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Kristensen, J. P. Christensen, and A. R. Thomsen High numbers of IL-2-producing CD8+ T cells during viral infection: correlation with stable memory development J. Gen. Virol., September 1, 2002; 83(9): 2123 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Higgins, M. A. Mihalyo, P. W. McGary, and A. J. Adler CD4 Cell Priming and Tolerization Are Differentially Programmed by APCs upon Initial Engagement J. Immunol., June 1, 2002; 168(11): 5573 - 5581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Roth, J. Schwartzkopff, and H. Pircher CD40 Ligation in the Presence of Self-Reactive CD8 T Cells Leads to Severe Immunopathology J. Immunol., May 15, 2002; 168(10): 5124 - 5129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Nguyen, A. R. Elford, K. Murakami, K. M. Garza, S. P. Schoenberger, B. Odermatt, D. E. Speiser, and P. S. Ohashi Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance J. Exp. Med., February 11, 2002; 195(4): 423 - 435. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
